Tata India Pharma & Healthcare Fund
This is the Regular plan of Tata India Pharma & Healthcare Fund — bought through a distributor, whose commission is paid out of its expense ratio. Income is retained in the fund, so it shows up as NAV rather than as a payout.
Performance
Scorecard
★★★★☆4/5 vs 145 of 257 Sectoral/ Thematic peers- Performance 60%
- Risk 15%
- Cost 10%
- Downside 15%
How this is computed
Each verdict is computed from this fund's own metrics against its sub-category — the number behind it is shown, not a black-box rating. The stars weight the same ground 60/15/10/15 (performance/risk/cost/downside) across every fund in the peer group. Ranked within Sectoral/ Thematic (same plan and option). 145 of the 257 Sectoral/ Thematic funds in this cohort carry the full record the stars need, so they are the ones ranked against.
3Y CAGR +16.66% · ranks 39 of 145 Sectoral/ Thematic funds
Volatility 13.4% vs 15.8% category avg
2.4% expense vs 2.5% category avg
88% of rolling 3Y windows were positive
Strengths & concerns
Generated from this fund's own numbers against its sub-category — each point names the figure behind it.
Strengths
- 1-year return (+9.16%) beats the Sectoral/ Thematic average (+4.44%)
- 3-year return (+16.66%) beats the Sectoral/ Thematic average (+13.01%)
- 5-year return (+14.11%) beats the Sectoral/ Thematic average (+11.74%)
- Stronger risk-adjusted returns — Sharpe 0.76 vs 0.40 Sectoral/ Thematic average
- Less volatile than its Sectoral/ Thematic peers (13.4% vs 15.8%)
Concerns
No significant concerns identified.
Key Metrics
Scheme Info
DefinitionsPeriod returns (<1Y, absolute — not annualized)
DefinitionsAnnualized returns (≥1Y — CAGR)
DefinitionsAdvanced metrics — risk and benchmark ratios
Fund vs category average (Sectoral/ Thematic)
| Period | Fund | Category avg. | Diff |
|---|---|---|---|
| 1M abs | +8.71% | +6.05% | +2.66% |
| 3M abs | -0.34% | +0.26% | -0.60% |
| 6M abs | +5.67% | +7.32% | -1.65% |
| 1Y CAGR | +9.16% | +4.44% | +4.72% |
| 3Y CAGR | +16.66% | +13.01% | +3.65% |
| 5Y CAGR | +14.11% | +11.74% | +2.37% |
Category average across peers in Sectoral/ Thematic (up to 257 funds with data), same plan and option, excluding this fund. Under-1-year figures are absolute; 1Y and beyond are annualised (CAGR).
Not sure what a figure means? The glossary explains every metric, and the methodology shows the formulas.
Category rank
Vs 257 peers in Sectoral/ Thematic
Backtest this fund
What a SIP or one-time investment would have grown to over this fund’s real NAV history.
60 monthly installments of ₹10,000 into Tata India Pharma & Healthcare Fund, valued at the latest NAV. XIRR annualizes for each installment’s timing.
Calendar-year returns
What the fund actually returned in each year, not the smoothed average.
| Year | Fund | Nifty Healthcare TRI | Diff | |
|---|---|---|---|---|
| 2026part | +11.28% | +19.00% | -7.72% | |
| 2025 | -4.92% | -1.53% | -3.39% | |
| 2024 | +40.40% | +41.34% | -0.94% | |
| 2023 | +36.58% | +33.89% | +2.69% | |
| 2022 | -8.04% | -10.17% | +2.13% | |
| 2021 | +19.07% | +19.01% | +0.06% | |
| 2020 | +64.38% | — | — | |
| 2019 | +5.51% | — | — | |
| 2018 | -2.62% | — | — | |
| 2017 | +4.65% | — | — |
January–December, from this fund's NAV history. Absolute return, not annualised. “part” marks a year the fund didn't run end to end — its first year, the current year so far, or one it stopped reporting in; those years show no benchmark comparison.
Taxation
Taxed as equityThis is an equity-oriented fund (≥65% in Indian equities), so gains get the concessional capital-gains rates below — they do not add to your income-tax slab.
Flat, on the whole gain
On gains above ₹1.25 L per financial year
Applies to capital gains on redemption. Excludes IDCW/dividend tax, STT, surcharge and cess, and pre-2018 equity grandfathering. For research only — consult a tax advisor before filing.
Asset allocation
As on 31 Oct 2026 · AMC disclosure- Equity99.74%
- Cash & Equivalents0.26%
Fund size over time
Quarterly average AUM · AMFIAt or near its largest, ₹1,534Cr in July - September 2026. Size matters most where the mandate is narrow — a large small-cap or a very large flexi-cap book is harder to move without moving the price.
AMC Profile
Tata Mutual Fund is run by Tata Asset Management, part of the Tata Group, and has been in business since 1995. It runs a broad line-up across equity, debt and hybrid, including several long-running thematic schemes.
Fund Managers
RSRajat SrivastavaStart date not disclosed
BBA (Banking & Insurance), Ghaziabad
Fund manager, benchmark and dealing terms from this scheme's SEBI-filed Scheme Information Document on AMFI. Each manager's qualifications and role are reconciled across every filing this fund house makes for them, including its Statement of Additional Information. Total AUM via AMFI.
Explore from here
Tata in the news
Headlines about the fund house, not this scheme in particular — highlights only; tap through to read the full story at the source.
Three US tech giants worth $13 trillion; India's entire market at $5 trillion: What should investors make
The Economic Times · 12h ago
Mahanadi Coalfields IPO Opens Today: Rs 2,295 Crore Raised From Anchor Investors; GMP, Price Details
ETV Bharat · 15h ago
Mahanadi Coalfields Raises Rs 2,295 Crore From Anchor Investors Ahead of IPO
HDFC Sky · 16h ago
Goldman Sachs, Citigroup, Morgan Stanley help Mahanadi Coalfields mop up Rs 2,295 crore from anchor invest
The Economic Times · 1d ago
Mahanadi Coalfields Raises ₹2,295 Cr from Anchor Investors
Rediff MoneyWiz · 1d ago
Kotak MF, BlackRock, others buy stake worth Rs 1,905 cr in Groww
The Economic Times · 1d ago
Star Health adds Nov 23 analyst meetings in Pune with Bajaj firms
scanx.trade · 1d ago
Groww Attracts ₹1,905 Crore Institutional Buying, Kotak MF And BlackRock Step In As Ribbit Capital Trims
Free Press Journal · 1d ago
Returns and risk are computed from NAV history and may differ slightly from other portals due to methodology (rolling vs point-to-point, dividend treatment). For research only — not investment advice.
About Sectoral & Thematic funds
Sectoral and thematic funds must keep at least 80% in the equity of one sector (banking, pharma, technology) or one theme (consumption, manufacturing, ESG). That concentration is the point and the risk: with no mandate to diversify away from the sector, the fund rises and falls with it.
Frequently asked questions
What is the NAV of Tata India Pharma & Healthcare Fund?
As of 19 Nov 2026, the NAV of Tata India Pharma & Healthcare Fund is ₹33.62 per unit. NAV (net asset value) is the fund's per-unit price, published once each business day.
What returns has Tata India Pharma & Healthcare Fund delivered?
Tata India Pharma & Healthcare Fund has returned +9.16% over 1 year, +16.66% per year over 3 years, +14.11% per year over 5 years and +11.74% per year since inception. Figures beyond one year are annualised (CAGR) and are computed from AMFI NAV history, so they may differ slightly from other portals.
What is the expense ratio of Tata India Pharma & Healthcare Fund?
Tata India Pharma & Healthcare Fund charges an expense ratio of 2.42% per year. This annual fee is already deducted from the NAV, so the returns you see are net of it.
What are the top holdings of Tata India Pharma & Healthcare Fund?
Tata India Pharma & Healthcare Fund's largest holdings are SUN PHARMACEUTICAL INDUSTRIES LTD (7.9%), ABBOTT INDIA LTD (5.7%), DIVI LABORATORIES LTD (5.4%), HEALTHCARE GLOBAL ENTERPRISES LTD (5.3%) and DR REDDYS LABORATORIES LTD (5.1%). Holdings are disclosed monthly and change over time.
How risky is Tata India Pharma & Healthcare Fund?
Tata India Pharma & Healthcare Fund sits at the very high level on our estimate of SEBI's risk-o-meter scale, its trailing-3Y volatility (annualised) is 13.4% and its worst peak-to-trough fall in our sample was 21.9%. Higher volatility means the NAV swings more; the drawdown shows how far it has fallen from a peak historically.
What does the Sharpe ratio of 0.76 mean?
The Sharpe ratio is return earned per unit of total risk, above a 6.5% risk-free rate. Tata India Pharma & Healthcare Fund's 0.76 means it has rewarded its volatility with excess return. Higher is better.
What is the benchmark of Tata India Pharma & Healthcare Fund?
Tata India Pharma & Healthcare Fund is benchmarked against the BSE Healthcare TRI. The alpha, beta and capture figures on this page are measured against the Nifty Healthcare TRI, the closest index whose daily history we hold.
Who manages Tata India Pharma & Healthcare Fund?
Tata India Pharma & Healthcare Fund is managed by Rajat Srivastava at Tata.
When was Tata India Pharma & Healthcare Fund launched, and what is its objective?
Tata India Pharma & Healthcare Fund was launched on 28 Dec 2015. its stated objective is: The investment objective of the scheme is to seek long term capital appreciation by investing atleast 80% of its net assets in equity/equity related instruments of the companies in the pharma & healthcare sectors in India.However, there is no assurance or guarantee that the investment objective of…. Both are as filed in the scheme's own Scheme Summary Document.
How is Tata India Pharma & Healthcare Fund taxed?
Tata India Pharma & Healthcare Fund is an equity-oriented fund, so its capital gains get concessional rates: short-term gains (units held under 1 year) are taxed at 20%, and long-term gains (held 1 year or more) at 12.5% above a ₹1.25 lakh per-year exemption. These rates apply on redemption and don't add to your income-tax slab.